Your browser is no longer supported. Please, upgrade your browser.
EPZM [NASD]
Epizyme, Inc.
Index- P/E- EPS (ttm)-2.29 Insider Own1.00% Shs Outstand101.60M Perf Week6.15%
Market Cap871.86M Forward P/E- EPS next Y-1.80 Insider Trans3.20% Shs Float82.71M Perf Month-1.54%
Income-231.70M PEG- EPS next Q-0.58 Inst Own99.00% Short Float16.22% Perf Quarter-24.64%
Sales15.80M P/S55.18 EPS this Y-19.10% Inst Trans0.07% Short Ratio10.77 Perf Half Y-36.72%
Book/sh1.46 P/B5.68 EPS next Y22.40% ROA-53.40% Target Price- Perf Year-53.24%
Cash/sh3.55 P/C2.33 EPS next 5Y38.00% ROE-100.90% 52W Range6.70 - 22.00 Perf YTD-23.66%
Dividend- P/FCF- EPS past 5Y7.10% ROI-59.60% 52W High-62.32% Beta1.26
Dividend %- Quick Ratio9.10 Sales past 5Y43.80% Gross Margin67.90% 52W Low23.73% ATR0.51
Employees304 Current Ratio9.30 Sales Q/Q95.30% Oper. Margin- RSI (14)52.44 Volatility7.41% 5.45%
OptionableYes Debt/Eq1.54 EPS Q/Q-10.00% Profit Margin- Rel Volume2.51 Prev Close6.81
ShortableYes LT Debt/Eq1.54 EarningsMay 06 BMO Payout- Avg Volume1.25M Price8.29
Recom2.10 SMA204.57% SMA50-2.36% SMA200-26.86% Volume3,129,383 Change21.73%
May-07-21Upgrade SVB Leerink Mkt Perform → Outperform $12 → $16
Apr-23-21Resumed Cowen Outperform $14
Mar-31-21Initiated Credit Suisse Outperform $13
Feb-25-21Downgrade Morgan Stanley Overweight → Equal-Weight $14
Dec-21-20Downgrade Jefferies Buy → Hold $14
Apr-01-20Downgrade Oppenheimer Outperform → Perform
Mar-04-20Initiated Barclays Overweight $33
Feb-25-20Reiterated H.C. Wainwright Buy $25 → $36
Jan-24-20Downgrade SVB Leerink Outperform → Mkt Perform
Dec-06-19Upgrade Morgan Stanley Equal-Weight → Overweight
May-30-19Resumed Citigroup Buy
Jan-07-19Upgrade Leerink Partners Mkt Perform → Outperform
Sep-07-18Resumed Morgan Stanley Equal-Weight
Jul-03-18Downgrade Leerink Partners Outperform → Mkt Perform
Jan-24-18Resumed Jefferies Buy $25
Jan-10-18Initiated Morgan Stanley Overweight $20
Nov-02-17Downgrade RBC Capital Mkts Outperform → Sector Perform $20 → $16
Sep-20-17Initiated Jefferies Buy $23
May-10-17Resumed RBC Capital Mkts Outperform $19 → $20
Apr-13-17Initiated Oppenheimer Outperform
May-07-21 05:30PM  
08:44AM  
07:24AM  
May-06-21 08:05AM  
06:30AM  
Apr-29-21 06:30AM  
Apr-01-21 12:13PM  
Mar-25-21 11:30AM  
Mar-02-21 12:00PM  
Feb-28-21 01:34AM  
Feb-25-21 10:03AM  
Feb-24-21 06:30AM  
Feb-23-21 08:00PM  
10:31AM  
10:04AM  
07:24AM  
06:15AM  
Feb-20-21 09:36AM  
Feb-16-21 06:30AM  
Jan-25-21 07:52AM  
Dec-18-20 02:43PM  
Dec-06-20 11:30AM  
Nov-29-20 12:30PM  
Nov-16-20 05:16AM  
Nov-15-20 11:16PM  
Nov-13-20 12:56PM  
Nov-11-20 04:05PM  
06:15AM  
Nov-10-20 05:50AM  
Nov-09-20 10:16AM  
Nov-08-20 09:24AM  
Nov-06-20 07:31PM  
07:53AM  
07:45AM  
06:30AM  
06:05AM  
06:00AM  
Oct-30-20 06:30AM  
Oct-28-20 12:33PM  
Oct-07-20 03:29PM  
06:30AM  
Oct-02-20 09:21AM  
Sep-08-20 06:30AM  
Sep-03-20 11:31AM  
Aug-18-20 01:05PM  
Aug-05-20 11:29AM  
Aug-04-20 05:00PM  
07:45AM  
07:18AM  
06:30AM  
Jul-28-20 06:30AM  
Jul-16-20 06:31PM  
Jun-28-20 09:31AM  
Jun-20-20 07:57AM  
Jun-19-20 10:19AM  
10:02AM  
09:41AM  
Jun-18-20 01:31PM  
08:34AM  
Jun-17-20 01:56PM  
Jun-16-20 07:09AM  
Jun-03-20 11:30AM  
May-26-20 12:55PM  
May-14-20 09:22AM  
May-13-20 05:12PM  
May-07-20 10:51AM  
May-05-20 09:11AM  
May-04-20 07:00PM  
07:45AM  
07:04AM  
06:30AM  
Apr-27-20 12:32PM  
06:30AM  
Apr-26-20 10:02AM  
Apr-19-20 07:02AM  
Apr-08-20 06:56PM  
Mar-25-20 11:30AM  
Mar-20-20 06:30AM  
Mar-06-20 03:41AM  
Feb-26-20 06:39AM  
Feb-25-20 12:09PM  
09:38AM  
09:28AM  
05:17AM  
Feb-24-20 07:45AM  
06:30AM  
06:30AM  
Feb-23-20 06:38PM  
Feb-20-20 08:42AM  
Feb-19-20 09:21AM  
Feb-18-20 06:30AM  
Feb-14-20 08:23AM  
06:30AM  
Feb-12-20 06:55AM  
Feb-06-20 05:50PM  
Feb-05-20 11:52AM  
Jan-31-20 05:50PM  
Jan-29-20 09:59AM  
Jan-24-20 12:00PM  
10:44AM  
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops Tazemetostat in combination with rituximab in patients with follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and adults and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. Epizyme, Inc. has collaboration agreements with Genentech Inc.; Glaxo Group Limited; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; and Eisai Co. Ltd. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kutok JefferyChief Scientific OfficerApr 05Sale8.802,02917,85554,028Apr 07 06:15 AM
MOTT DAVID MDirectorMar 26Buy7.9734,486274,817150,900Mar 29 04:30 PM
MOTT DAVID MDirectorMar 25Buy7.9828,231225,283116,414Mar 29 04:30 PM
Bazemore Robert BPresident & CEOMar 25Sale7.8510,32881,075322,626Mar 29 04:30 PM
Bazemore Robert BPresident & CEOFeb 04Sale11.213,89043,607331,977Feb 05 04:41 PM
Beaulieu JosephCorporate ControllerFeb 04Sale11.212272,54513,431Feb 05 04:40 PM
TOMBESI PAOLOChief Financial OfficerFeb 04Sale11.211,02111,44553,465Feb 05 04:40 PM
Agarwal ShefaliChief Medical OfficerFeb 04Sale11.2196910,862104,341Feb 05 04:41 PM
Ros MatthewSee RemarksFeb 04Sale11.2189410,02283,188Feb 05 04:36 PM
Vakiener VictoriaChief Commercial OfficerFeb 04Sale11.218179,15952,685Feb 05 04:32 PM
Bazemore Robert BPresident & CEOJan 25Sale11.416,06969,247248,367Jan 27 08:44 PM
Ros MatthewSee RemarksJan 25Sale11.412,87232,77055,957Jan 27 08:42 PM
Vakiener VictoriaChief Commercial OfficerJan 25Sale11.415996,83527,982Jan 27 08:42 PM
Agarwal ShefaliChief Medical OfficerJan 25Sale11.412,87232,77075,727Jan 27 08:38 PM
Agarwal ShefaliChief Medical OfficerDec 03Sale13.542,52234,14876,089Dec 07 07:00 AM
GOLDFISCHER CARLDirectorNov 11Buy12.075,00060,3505,000Nov 13 07:05 AM
Beaulieu JosephCorporate ControllerSep 02Sale12.885436,9945,958Sep 03 09:30 PM
MOTT DAVID MDirectorJun 26Buy16.0362,019994,16582,601Jun 26 07:12 PM
Beaulieu JosephCorporate ControllerJun 26Sale16.153175,1204,838Jun 30 09:04 AM
Bazemore Robert BPresident & CEOJun 26Sale16.154,77377,084250,098Jun 30 09:01 AM
Agarwal ShefaliChief Medical OfficerJun 26Sale16.151,80529,15178,611Jun 30 08:56 AM
TOMBESI PAOLOChief Financial OfficerJun 26Sale16.151,80529,15121,942Jun 30 08:57 AM
Ros MatthewSee RemarksJun 26Sale16.152,72844,05757,507Jun 30 08:54 AM
Ros MatthewSee RemarksJun 18Option Exercise9.47112,0031,060,669120,449Jun 22 07:31 PM
Bazemore Robert BPresident & CEOJun 18Option Exercise8.9810,00089,800264,371Jun 22 07:36 PM
Bazemore Robert BPresident & CEOJun 18Sale22.0020,000440,000244,371Jun 22 07:36 PM
Ros MatthewSee RemarksJun 18Sale21.24112,0032,378,44451,798Jun 22 07:31 PM